Kazia Therapeutics reports 100% clinical benefit in first six TNBC patients
Kazia Therapeutics said it saw a 100% clinical benefit rate in its initial six treated patients with advanced triple-negative breast cancer.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.